Precigen

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Precigen (PGEN) reports strong Q1 performance and growth opportunities

Precigen's Q1 2023 earnings call highlighted financial strength, progress in innovative therapies, and a focus on cost-effective drug development.
The company's platforms like PRGM 2012 and UltraCAR show promise in treating challenging diseases, supported by a solid cash runway into late 2024.
While facing challenges in program transparency and target rights, Precigen's opportunities lie in rapid commercialization, personalized medicine, and market expansion.

Precigen (PGEN) reports strong Q2 performance and FDA alignment

Precigen (PGEN) shows promising performance with positive Phase I data for PRGN-2012 and cost-saving measures implemented.
Strengths lie in FDA confirmation, positive regulatory developments, and extended cash runway to 2025.
Challenges include safety follow-up, commercial readiness, and balancing program focus amidst cost-saving measures.
Opportunities arise from international licensure discussions, repeat dosing scenarios, and FDA alignment for accelerated approval.

Precigen (PGEN) projects strong growth in 2024 with key milestones

Precigen (PGEN) anticipates a significant year ahead with key milestones for PRGN-2012 and UltraCAR-T therapies.
Financially, the company aims to balance R&D investments with cost reductions to support strategic initiatives.
Analysts' inquiries and the focus on strengthening the balance sheet underscore the company's commitment to sustainable growth.

Precigen (PGEN) excels with PRGN-2012 gene therapy, poised for growth

Precigen (PGEN) showcased strong performance with PRGN-2012, supported by positive clinical trial outcomes and regulatory milestones.
While challenges like trial enrollment pace and market strategies exist, strategic initiatives and financial updates indicate a proactive approach to addressing them.
The company's focus on commercialization and workforce optimization presents opportunities for growth and market leadership in the gene therapy sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Precigen (NASDAQ:PGEN) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 61.54% year over year to ($0.10), which beat the estimate of ($0.12).

Precigen: Q2 Earnings Insights

GERMANTOWN, Md., Aug. 9, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced second quarter and first half 2021 financial results.

Precigen Reports Second Quarter and First Half 2021 Financial Results

GERMANTOWN, Md., Aug. 2, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first half 2021 financial results after the market closes on Monday, August 9, 2021.

Precigen to Announce Second Quarter and First Half 2021 Financial Results on August 9th

Precigen Inc's (NASDAQ: PGEN) subsidiary Precigen ActoBio announced topline results from the Phase 1b/2a study evaluating AG019 ActoBiotics to treat recent-onset type 1 diabetes (T1D). Results were presented at the Federation of Clinical Immunology Societies 2021.

Precigen Stock Surges On Positive AG019 Data for Chronic Treatment Of Type 1 Diabetes

GERMANTOWN, Md., June 10, 2021 /PRNewswire/ -- Precigen ActoBio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a wholly-owned subsidiary of Precigen, Inc. (Nasdaq: PGEN), today announced positive topline results for the ongoing Phase 1b/2a clinical study investigating AG019 ActoBiotics™ for the treatment of recent-onset type 1 diabetes (T1D) (clinical trial identifier: NCT03751007, EudraCT 2017-002871-24).

Precigen ActoBio Announces Positive Topline Results from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes

GERMANTOWN, Md,, June 10, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat at the annual JMP Securities Life Sciences Conference on Thursday, June 17, 2021 at 11:00 AM ET.  Participants may access the live webcasts of the virtual events through Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.

Precigen to Present at the JMP Securities Life Sciences Conference

GERMANTOWN, Md., May 10, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter 2021 financial results.

Precigen Reports First Quarter 2021 Financial Results

Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Precigen, Inc. (PGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Cancer treatment has evolved from the use of chemotherapeutic anti-tumor drugs to targeted therapies to monoclonal antibodies to immunotherapies to new, personalized therapeutics. Precigen, Inc. (NASDAQ: PGEN) is a biopharma pursuing a differentiated approach toward a cancer cure, and CEO Helen Zabsevari, who has strong academic credentials and has found equal success in the business arena, spoke with Benzinga about the company's products and platforms.

Exclusive: Precigen's CEO Breaks Down Biotech's Oncology Platforms, Technology, Differentiators

GERMANTOWN, Md., March 30, 2021 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that by mutual agreement Rick Sterling is stepping down from his position as Chief Financial Officer effective April 2, 2021.

Precigen Announces Departure of Chief Financial Officer

GERMANTOWN, Md., March 23, 2021 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the first patient has been dosed in the Phase I study of PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) AdenoVerse™ immunotherapy in adult patients with recurrent respiratory papillomatosis (RRP) (clinical trial identifier: NCT04724980).

Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)

GERMANTOWN, Md., March 18, 2021 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) AdenoVerse™ immunotherapy for recurrent respiratory papillomatosis (RRP).

Precigen Receives FDA Orphan Drug Designation for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)

Precigen, Inc. (PGEN) CEO Helen Sabzevari on Q4 2020 Results - Earnings Call Transcript

Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 31.25% and -16.13%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates

GERMANTOWN, Md., March 1, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced fourth quarter and full year 2020 financial results. "2021...

Precigen Reports Fourth Quarter and Full Year 2020 Financial Results

Will Precigen, Inc. (PGEN) Report Negative Q4 Earnings? What You Should Know

Clovis Oncology

Cenntro Electric Group

The next GME will be hard to find, but these three stocks could be solid candidates for a potential short squeeze. The post 3 Troll-able Stocks That Could Be the Next GME appeared first on InvestorPlace.

3 Troll-able Stocks That Could Be the Next GME

GERMANTOWN, Md., Feb. 4, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will...

Precigen to Participate in Guggenheim Healthcare Talks Oncology Day

Dynavax Technologies

Lannett Company

OPKO Health

Senseonics Holdings

TherapeuticsMD

United Microelectronics

VBI Vaccines

The movement of retail traders against hedge funds has caused several stocks to spike. Many of the top movers have been stocks that have a high percentage of their floated shares short, causing what's known as a short squeeze.

10 Short Squeeze Candidates Under $10

GERMANTOWN, Md., Jan. 26, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) announced today the closing of its previously announced underwritten public offering of common stock. Precigen sold 17,250,000 shares of its common stock at a public offering price of $7.50 per share, including...

Precigen Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

GERMANTOWN, Md., Jan. 22, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $7.50 per share. Precigen has also granted the underwriters a 30-day option to...

Precigen Announces Pricing of $112.5 Million Public Offering of Common Stock

GERMANTOWN, Md., Jan. 21, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced it has commenced an underwritten public offering of shares of its common stock. In addition, Precigen intends to grant the underwriters a 30-day option to purchase additional shares of its common...

Precigen Announces Proposed Public Offering of Common Stock

GERMANTOWN, Md., Jan. 13, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented clinical and preclinical updates at the 39th Annual J.P. Morgan...

Precigen Provides Pipeline Updates at the 39th Annual J.P. Morgan Healthcare Conference

GERMANTOWN, Md., Jan. 6, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will...

Precigen to Present at the 39th Annual J.P. Morgan Healthcare Conference

GERMANTOWN, Md., Jan. 5, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has cleared the...

Precigen Announces Clearance of IND to Initiate Phase I Study of PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)

News for Precigen Stock (PGEN)